As reported on ScienceDaily, researchers at the University of Virginia (UVA) have developed an experimental treatment strategy that could address two of the biggest challenges in glioblastoma care: targeting the disease’s complex genetic drivers and overcoming the brain’s protective blood-brain barrier.
Glioblastoma is the most common malignant brain tumor in adults and remains one of the most aggressive cancers to treat. Standard care typically includes surgery, radiation therapy, and chemotherapy, but outcomes remain poor because tumor cells often infiltrate healthy brain tissue, making complete surgical removal difficult. In addition, the blood-brain barrier prevents many potentially effective therapies from reaching tumors.
To tackle these obstacles, a UVA research team led by Roger Abounader, MD, PhD, is investigating the use of microRNAs, small genetic molecules capable of regulating the activity of multiple genes involved in cancer growth. Unlike many conventional therapies that focus on a single molecular target, microRNAs may simultaneously suppress several pathways that help glioblastoma cells survive and spread.
The researchers paired these genetic molecules with nanoparticles and a focused ultrasound delivery system. Guided by MRI, the ultrasound is directed precisely at tumor sites while microscopic bubbles temporarily open the blood-brain barrier. This brief opening allows nanoparticles carrying the microRNAs to enter the brain and reach cancer cells.
Preclinical testing in laboratory studies and animal models demonstrated encouraging results. The treatment reduced tumor growth and extended survival compared with untreated controls, suggesting the approach may have therapeutic potential in glioblastoma.
According to the investigators, the strategy could offer advantages over combinations of traditional cancer drugs, which can cause significant toxicity. By using microRNAs to influence several cancer-promoting genes at once, the treatment may address pathways that currently lack effective drug targets.
Although the findings are promising, the therapy remains in the experimental stage. Additional research will be required before human clinical trials can determine its safety and effectiveness in patients. Researchers also believe the platform could eventually be adapted for other brain tumors and neurological diseases that are difficult to treat because of the blood-brain barrier.
The study was published in the Journal of Clinical Investigation and reported no financial conflicts of interest among the investigators. Funding was provided by the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, the UVA Comprehensive Cancer Center, the Schiff Foundation, the Ben and Catherine Ivy Foundation, and the Focused Ultrasound Foundation.
If future studies confirm these early results, the combination of focused ultrasound, nanoparticle delivery, and microRNA-based therapy could represent a new direction in the treatment of glioblastoma and other difficult-to-reach cancers.
